Two Armistice Capital directors resign from Tenax board; Armistice waives appointment right

TENAX THERAPEUTICS, INC.

Steven Boyd and Keith Maher resigned from Tenax board effective June 10, 2022; no disagreement cited.
Boyd and Maher were designees of Armistice Capital Master Fund Ltd., which had right to appoint two directors.
On June 13, 2022, Armistice irrevocably waived its appointment right under the July 2020 Purchase Agreement.
The waiver eliminates Armistice's ability to designate future board members.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Keith Maher

Director

TENX · TENAX THERAPEUTICS, INC.

Effective: 2022-06-10
Filed: June 16, 2022, 7:59 PM ET

On June 10, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) that they have resigned from the Board.

Departed

Steven Boyd

Director

TENX · TENAX THERAPEUTICS, INC.

Effective: 2022-06-10
Filed: June 16, 2022, 7:59 PM ET

On June 10, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) that they have resigned from the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith Maher resigned as Director at TENAX THERAPEUTICS, INC..

Action: resigned
Role: Director

Exact text from the filing

On June 10, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) that they have resigned from the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Boyd resigned as Director at TENAX THERAPEUTICS, INC..

Action: resigned
Role: Director

Exact text from the filing

On June 10, 2022, Steven Boyd and Keith Maher, MD, both of Armistice Capital, LLC, the investment manager to Armistice Capital Master Fund Ltd. (the “Master Fund”), notified the Board of Directors (the “Board”) of Tenax Therapeutics, Inc. (the “Company”) that they have resigned from the Board.

View on SEC.gov

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-22-008452

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.